Condition: Renal Cancer · Sponsor: Istituto Clinico Humanitas
The study objective is to evaluate the use of Stereotactic Body Radiotherapy (high dose of radiation in a few fractions) to cure primary renal cancer in those patients that are not indicated to surgery (high risk of complications, refusal of the patient). This therapy is already used in clinical setting for many tumors with good tolerance as it is not invasive, does not require anesthesia and hospitalization making it suitable for elderly people and frail patients. However there are not enough information regarding the use of ablative doses for the cure of renal cancer and for this reason this study aims to support the use of Stereotactic Body Radiotherapy as a standard of care for inoperable primary renal tumor. This is an observational study, so it collects data from clinical pratice only and does not request study specific procedures.
This description comes directly from the study's public registry record.
Ciro Franzese, MD, radiation oncologist · +39 0282247454 · ciro.franzese@hunimed.eu
Laura Bonavita, Master's degree · +390282247026 · laura.bonavita@humanitas.it
Always discuss trial participation with your own doctor first.
| Humanitas PIO X | Milan, Milan, Italy | Not Yet Recruiting |
| Irccs Humanitas Research Hospital | Rozzano, Milan, Italy | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07299357